Treatment of Allergic Asthma with Fenretinide Formulation (LAU-7b) Downregulates ORMDL Sphingolipid Biosynthesis Regulator 3 (Ormdl3) Expression and Normalizes Ceramide Imbalance
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73601246" target="_blank" >RIV/61989592:15110/20:73601246 - isvavai.cz</a>
Result on the web
<a href="https://obd.upol.cz/id_publ/333181132" target="_blank" >https://obd.upol.cz/id_publ/333181132</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1124/jpet.119.263715" target="_blank" >10.1124/jpet.119.263715</a>
Alternative languages
Result language
angličtina
Original language name
Treatment of Allergic Asthma with Fenretinide Formulation (LAU-7b) Downregulates ORMDL Sphingolipid Biosynthesis Regulator 3 (Ormdl3) Expression and Normalizes Ceramide Imbalance
Original language description
Allergic asthma causes global health burdens as it affects millions of people worldwide. Being a complex disease, in addition to environmental exposures, several genetically controlled factors greatly influence the predisposition and severity of allergic asthma (Burbank et al. 2017). Genome wide association studies (GWAS) have highlighted the 17q21 locus, which contains several susceptibility genes including Zona pellucida binding protein 2 (ZPBP2) and ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3), on human chromosome 17 and their orthologs Zpbp2 and Ormdl3 on mouse chromosome 11, as a well-established susceptible locus for airway hyperresponsiveness (AHR) (Moffatt et al. 2007). The 17q21 locus importance was evaluated in an ethnically diverse population but ethnic-based differences were not found (Kothari et al. 2018).
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
—
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
ISSN
0022-3565
e-ISSN
—
Volume of the periodical
373
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
476-487
UT code for WoS article
000551159700015
EID of the result in the Scopus database
2-s2.0-85085157460